Comparative Pharmacology
Head-to-head clinical analysis: SELENOMETHIONINE SE 75 versus SPECTAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELENOMETHIONINE SE 75 versus SPECTAMINE.
SELENOMETHIONINE SE 75 vs SPECTAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
SPECTAMINE (iofetamine I-123) is a radiopharmaceutical that crosses the blood-brain barrier and localizes in the brain proportional to regional cerebral blood flow. It binds to striatal dopamine transporters (DAT) and is used as a marker for dopamine transporter density.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
SPECTAMINE (technetium Tc-99m exametazime) is administered intravenously. For brain imaging, the recommended adult dose is 10-20 mCi (370-740 MBq). For white blood cell labeling, the dose is 10-20 mCi (370-740 MBq) after labeling autologous leukocytes.
None Documented
None Documented
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Terminal elimination half-life: 13-17 hours; clinically, effective half-life for brain SPECT imaging is 6-9 hours due to redistribution.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Renal: >90% as unchanged drug within 24 hours; biliary/fecal: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical